FAP and malignant colon neoplasm: With the reference molecule, the percent of the maximum pharmacological effect was 80% (at the qw schedule) for the virtual patient population with colon cancer indication, compared to 93% with the molecule with a 10-fold increase in FAP-binding affinity.